Trial Profile
An Observational Post-Authorization Modified Prescription-Event Monitoring Safety Study to Monitor the Safety and Utilization of Asenapine (Sycrest) in the Primary Care Setting in England
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Asenapine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 26 Jan 2018 Planned End Date changed from 1 May 2017 to 1 Mar 2018.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.